ArticleInvestigative ophthalmology & visual science2025
Determination of the Population Frequency of Monoallelic and Biallelic Predicted Pathogenic RPE65 Variants in a Normal Database.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The RPE65-associated retinopathies include biallelic Leber congenital amaurosis 2 and severe early childhood-onset RP, and monoallelic RP with choroidal involvement. The population frequencies of these diseases have previously only been estimated from epidemiological studies, but are deduced here from the number of predicted pathogenic heterozygous or carrier variants in a normal cohort using bioinformatic analyses. Methods: RPE65 variants were downloaded from gnomAD v4.1 (n = 807,162) and annotated with ANNOVAR. The population frequency of heterozygous predicted pathogenic variants was calculated from the numbers of pathogenic structural and copy number variants, null variants, rare missense changes classified disease-causing computationally, and from founder variants not already included. The computed population frequency for biallelic disease was compared with frequencies deduced from pathogenic variants reported in ClinVar. Results: The population frequencies of heterozygous predicted pathogenic RPE65 variants were 1 in 408 using our strategy and 1 in 415 using ClinVar. Variants were structural in 50 people (3%), null in 793 (41%), and missense in 1,115 (57%). Predicted pathogenic variants were commonest in Admixed American (1 in 257) and African American (1 in 268) and least common in Middle Eastern (1 in 3,031) and Ashkenazi (1 in 1,851) people. A possible founder variant (p.Tyr431His) was present in 1 in 21 Amish. The variant associated with monoallelic RPE65-retinopathy (p.Asp477Gly) was present in 1 in 294,930 Europeans. Conclusions: Biallelic RPE65-associated retinopathy affects at least 1 in 665,856 of the population, but is more common in Admixed Americans (1 in 264,196) and African Americans (1 in 287,296).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.